IBERDOMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H27N3O5
Molecular Weight	449.499
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1N(CC2=C1C=CC=C2OCC3=CC=C(CN4CCOCC4)C=C3)[C@H]5CCC(=O)NC5=O

InChI

InChIKey=IXZOHGPZAQLIBH-NRFANRHFSA-N

InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C25H27N3O5
Molecular Weight	449.499
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28425720 | https://www.ncbi.nlm.nih.gov/pubmed/28848067 | https://www.ncbi.nlm.nih.gov/pubmed/29945920

CC-220 is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines. CC-220 is currently under clinical investigation for systemic lupus erythematosus and multiple myeloma as a single agent, or in combination with dexamethasone in patients who may have previously been exposed to pomalidomide. Comparable to other Cereblon-binding agents, ex vivo treatment of CC-220 on B-cells, T-cells, and monocytes leads to the degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). followed by disruption of the multiple myeloma promoting c-Myc/IRF4 axis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Protein cereblon 10 Target ID: Q96SW2 Gene ID: 51185.0 Gene Symbol: CRBN Target Organism: Homo sapiens (Human) Sources: http://www.bloodjournal.org/content/128/22/1591	Binding Agent 1064

PubMed

Title	Date	PubMed
Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.	2017 Oct 1	28848067

Patents

Sample Use Guides

In Vivo Use Guide

0.3 mg for 21 days of a 28-day cycle

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:40:42 GMT 2023` Edited by `admin` on `Sat Dec 16 10:40:42 GMT 2023`
Record UNII	8V66F27X44
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IBERDOMIDE

Official Name

English

Iberdomide [WHO-DD]

Common Name

English

(3S)-3-[4-({4-[(Morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]piperidine-2,6-dione

Systematic Name

English

2,6-PIPERIDINEDIONE, 3-(1,3-DIHYDRO-4-((4-(4-MORPHOLINYLMETHYL)PHENYL)METHOXY)-1-OXO-2H-ISOINDOL-2-YL)-, (3S)-

Systematic Name

English

(S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE

Systematic Name

English

iberdomide [INN]

Common Name

English

CC-220

Code

English

IBERDOMIDE [USAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

665718